NASDAQ:ARAYAccuray Stock Price, Forecast & News

Accuray's stock was trading at $2.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARAY shares have decreased by 4.0% and is now trading at $2.18. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Accuray.

Accuray is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for Accuray.

Accuray Incorporated (NASDAQ:ARAY) released its quarterly earnings results on Tuesday, April, 28th. The medical equipment provider reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.07. The medical equipment provider earned $99.55 million during the quarter, compared to analysts' expectations of $96.46 million. Accuray had a net margin of 0.64% and a negative return on equity of 14.83%. View Accuray's earnings history.

4 Wall Street analysts have issued twelve-month target prices for Accuray's stock. Their forecasts range from $4.00 to $10.00. On average, they expect Accuray's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 221.1% from the stock's current price. View analysts' price targets for Accuray.

News coverage about ARAY stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Accuray earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Accuray.

Accuray saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 2,910,000 shares, a decline of 5.8% from the May 31st total of 3,090,000 shares. Based on an average trading volume of 620,700 shares, the short-interest ratio is presently 4.7 days. Approximately 3.4% of the shares of the company are sold short. View Accuray's Current Options Chain.

Some companies that are related to Accuray include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Activision Blizzard (ATVI), Intel (INTC), Tesla (TSLA), Corbus Pharmaceuticals (CRBP), Netflix (NFLX), Abeona Therapeutics (ABEO), Amarin (AMRN) and AVEO Pharmaceuticals (AVEO).

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Accuray's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Diversified Trust Co (0.02%). Company insiders that own Accuray stock include Andrew J Kirkpatrick, Jesse Chew, Joseph E Whitters, Joshua Levine, Patrick Spine and Shigeyuki Hamamatsu. View institutional ownership trends for Accuray.

ARAY stock was purchased by a variety of institutional investors in the last quarter, including Diversified Trust Co. Company insiders that have bought Accuray stock in the last two years include Joseph E Whitters, and Joshua Levine. View insider buying and selling activity for Accuray.

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARAY stock can currently be purchased for approximately $2.18.

Accuray has a market capitalization of $197.33 million and generates $418.79 million in revenue each year. The medical equipment provider earns $-16,430,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Accuray employs 998 workers across the globe.

The official website for Accuray is www.accuray.com.

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]